• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Email
  • Facebook
  • LinkedIn
  • YouTube

International Alliance of ALS/MND Associations

  • Members' Login
  • Contact
  • Join the Alliance
  • Donate
  • Understanding ALS/MND
    • What is ALS/MND
    • Genetics
    • Diagnosis
    • Glossary
    • Navigating the Community
  • Find a Member Association
  • Support for PALS & CALS
    • Fundamental Rights for People with ALS/MND and Caregivers
    • Research
      • Clinical Trial Registry Accuracy and Maintenance in ALS/MND Research
      • Open Science
        • Open Label Extension
      • Expanded Access
      • Understanding ALS/MND Research
      • Improving Regulatory Pathways
      • Right to Try
      • US FDA Orphan Drug Designation
      • Unproven Treatments
    • Advocacy
      • Advocacy Toolkit
      • Emergency Preparedness Toolkit
      • Equitable Access to Therapies
      • Recommendations for Trial Sponsors
    • Clinical Care
      • Genetic Counselling & Testing
      • Mental Health Support
      • Nursing and Symptom Management
      • Nutrition, Swallowing and Saliva
      • Activities of Daily Living and Occupational Therapy
      • Muscles, Mobility and Exercise
      • Respiratory Care
      • Speech and Communication
      • Voice Preservation
      • Support for Family & Caregivers
      • Technology
      • Global Clinic Locator
    • Drugs in Development
      • Masitinib
      • NurOwn
      • CNM-Au8
      • ILB
      • AstroRx
      • Neuronata-R / Lenzumestrocel
      • PrimeC
      • NP001
      • Pridopidine
      • SOD1 Therapies and Trials
      • C9orf72 Therapies and Trials
      • SPG302
      • Regulatory T Cell Enhancing Therapies
      • Ulefnersen
    • Approved Drugs
      • Nuedexta
      • Radicava / Edaravone
      • Riluzole / Tiglutik
      • Rozebalamin / Methylcobalamin
      • Tofersen / Qalsody
    • Drugs No Longer in Development
      • AMX0035
      • Reldesemtiv
      • Arimoclomol
      • TUDCA
      • CuATSM
  • Support for Health Professionals
    • Breaking the News in ALS/MND
    • R.A.C.E. to Diagnose ALS/MND
  • Programs & Events
    • Calendar of Events
    • Global Day Calendar
    • Alliance Meeting
    • Allied Professionals Forum
    • “Day in the Life Of” Suite
    • Alliance Webinars
    • ALS/MND Connect
    • March of Faces
    • Patient Fellows Program
    • Alliance Fellows
    • SEED Grant Program
    • Awards
      • Forbes Norris Award
      • Humanitarian Award
      • Allied Health Professional Award
      • Student Innovation Award
  • About
    • Who We Are
    • ALS/MND Health Literacy Map
    • Board of Trustees
    • Councils, Forums & Committees
      • Scientific Advisory Council
      • PALS and CALS Advisory Council
      • Advocacy and Public Policy Forum
      • Research Directors Forum
      • Governance Committee
      • Finance Committee
    • Staff
    • History
    • Newsletter Archive
  • Members
    • Member Registration
    • Forgot Password

TUDCA

Background

Tauroursodeoxycholic acid (TUDCA) is an acid present in the bile regularly produced in the human liver. TUDCA is commonly used for treatment of chronic liver conditions and for gallstone and it is thought to have a beneficial effect on mitochondria health. TUDCA has also been described as a protective agent for cellular cell death, and therefore, considered for the treatment of neurodegenerative diseases.

Trial Design & Results

A phase 2b proof of concept double blind placebo-controlled study was run in Italy from 2008 to 2012 on 34 individuals affected by ALS/MND. The trial enrolled early-stage non severely disabled individuals who were treated with 1g twice daily of TUDCA or placebo for 54 weeks and examined every 6 weeks. The primary outcome measure was the portion of responder individuals, defined as those showing an improvement of at least 15% in the ALS functional rating scale revised (ALSFRS-R) slope during treatment period compared to the lead in period (the stage before the start of the trial). The study reported that TUDCA was well tolerated, and that the portion of responders was higher in the TUDCA treated group compared to placebo, resulting in slower progression in the TUDCA treated group. However, this study was conducted on a relatively small number of individuals, and a phase 3 was deemed necessary to confirm TUDCA efficacy in slowing disease progression.

On the basis of the results of the phase 2b study, a larger multi center phase 3 placebo-controlled trial was designed using the same dosage of TUDCA and placebo. The trial aimed to recruit 440 people newly diagnosed with ALS in 26 centers across Italy, Germany, UK, France, the Netherlands and Ireland.  The delivery of the trial was impacted by the COVID-19 pandemic and recruitment was less than planned. The results from this trial were released in March 2024, the study ran for 18 months including a total of 336 people but failed to meet its primary endpoint, which was defined as a difference in responding and non-responding individuals in month 18 as measured by ALSFRS-R. Additionally, no difference was found between TUDCA and placebo in secondary outcome measures including time of survival and biomarker measurements. Treatment with TUDCA was well tolerated and generally safe.

TUDCA is also one of the two components of AMX0035, a compound developed by Amylyx Pharmaceuticals that was recently announced to have not met either primary or secondary endpoints in a phase 3 clinical trial.

Summary

Considering the available evidence, it is the opinion of the SAC that TUDCA is safe and tolerable. Given the available data, however, it is the opinion of the SAC that there is enough evidence to conclude that at the studied dosage, TUDCA did not show overall benefit in individuals living with ALS.

International Alliance of ALS/MND Associations
April 2026


Disclaimer: The original language of communication is English and any translation cannot be guaranteed for accuracy of messaging.

Primary Sidebar

  • Norm MacIsaac, Canada

    Norm MacIsaac, Canada

  • Brigitte Wernli, Switzerland

    Brigitte Wernli, Switzerland

  • Imelda Arenas, Colombia

    Imelda Arenas, Colombia

  • Chih Ching Darren Wong, Malaysia

    Chih Ching Darren Wong, Malaysia

  • Graham Johnson, Australia

    Graham Johnson, Australia

  • Animesh Kumar, India

    Animesh Kumar, India

  • Jorge Melo, Brazil

    Jorge Melo, Brazil

  • Gudjon Sigurdsson, Iceland

    Gudjon Sigurdsson, Iceland

  • Ana María Zavala, Mexico

    Ana María Zavala, Mexico

  • Sharon Corosanite, USA

    Sharon Corosanite, USA

  • Luis Antonio Pimenta Lima, Brazil

    Luis Antonio Pimenta Lima, Brazil

  • Jean Waters, UK

    Jean Waters, UK

  • Elkin Gaviria, Colombia

    Elkin Gaviria, Colombia

  • Frank Bos, Netherlands

    Frank Bos, Netherlands

  • Mark Miller, UK

    Mark Miller, UK

  • Mirca Bersani, Italy

    Mirca Bersani, Italy
    MircaBersani

  • John Russo, USA

    John Russo, USA
    final3878

  • Orlando Ruiz, Colombia

    Orlando Ruiz, Colombia

  • Claire Garry, USA

    Claire Garry, USA
    20200117_214643

  • Fayette Underwood, USA

    Fayette Underwood, USA

  • Phil Rossall, UK

    Phil Rossall, UK

  • Paul Launer, USA

    Paul Launer, USA

  • Kirsten Harley, Australia

    Kirsten Harley, Australia

  • Kirsty Gerlach, New Zealand

    Kirsty Gerlach, New Zealand

  • Bob Simonds, USA

    Bob Simonds, USA

  • Debbie Craghill, USA

    Debbie Craghill, USA

  • Lombana, Spain

    Lombana, Spain

  • Steven Gallagher, Canada

    Steven Gallagher, Canada

  • Jeff Sutherland, Canada

    Jeff Sutherland, Canada
    jspic

  • Monica Soriano, Argentina

    Monica Soriano, Argentina

  • Susan Anderson, USA

    Susan Anderson, USA

  • Willi Klein, UK

    Willi Klein, UK

  • Gisli Jonasson, Iceland

    Gisli Jonasson, Iceland

  • Robbie Caliste, UK

    Robbie Caliste, UK

  • Carlos Alberto Báez Murillo, Colombia

    Carlos Alberto Báez Murillo, Colombia

  • Patrick Shuma, Kenya

    Patrick Shuma, Kenya

  • Cath Muir, UK

    Cath Muir, UK
    Cath

  • John Sweeney, USA

    John Sweeney, USA

  • Calum Ferguson, Scotland

    Calum Ferguson, Scotland

  • Emilienne Verhaegen, Belgium

    Emilienne Verhaegen, Belgium

  • Lineke Veenstra, Netherlands

    Lineke Veenstra, Netherlands

  • Philip Brindle, England

    Philip Brindle, England

  • Ismail Gokcek, Turkey

    Ismail Gokcek, Turkey
    ismail_gokcek_alsmnd_tr

  • Lee Millard, England

    Lee Millard, England

  • Charlie Dourney, USA

    Charlie Dourney, USA

  • Natalya Rybakova, Russia

    Natalya Rybakova, Russia

  • Teddy Hanono Annie, Mexico

    Teddy Hanono Annie, Mexico

  • Oscar Mauricio Linares, Colombia

    Oscar Mauricio Linares, Colombia

  • Lucy Lintott, Scotland

    Lucy Lintott, Scotland

  • Erwin Coppejans, Belgium

    Erwin Coppejans, Belgium

Learn more about the March of Faces

Drugs No Longer in Development

  • AMX0035
  • Reldesemtiv
  • Arimoclomol
  • TUDCA

Footer

Stay connected to the global ALS/MND community.

Subscribe to receive our newsletter and updates on how to get involved across the Alliance network.

 
This field is for validation purposes and should be left unchanged.
  • Email
  • Facebook
  • LinkedIn
  • YouTube
Return to top of page

Contact | Disclaimer | Privacy Notice & Cookies | Sitemap

Copyright © 2026 The International Alliance of ALS/MND Associations. All rights reserved.


Registered in England: Charity Number 1079504 · Site built by graphics.coop · Powered by WordPress · Members' login